133 related articles for article (PubMed ID: 10547379)
1. Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?
Piantadosi S
J Natl Cancer Inst; 1999 Nov; 91(21):1794. PubMed ID: 10547379
[No Abstract] [Full Text] [Related]
2. Re: Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?
Meyskens FL
J Natl Cancer Inst; 2000 Feb; 92(3):274-5. PubMed ID: 10655448
[No Abstract] [Full Text] [Related]
3. Re: Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?
Veronesi U; De Palo G; Marubini E; Costa A; Mariani L; Formelli F; Decensi A
J Natl Cancer Inst; 2000 Feb; 92(3):274; author reply 274-5. PubMed ID: 10655447
[No Abstract] [Full Text] [Related]
4. Re: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
Ménard S; Camerini T; Mariani L; Tomasic G; Pilotti S; Costa A; De Palo G; Veronesi U
J Natl Cancer Inst; 2001 Feb; 93(3):240-1. PubMed ID: 11158198
[No Abstract] [Full Text] [Related]
5. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
Veronesi U; De Palo G; Marubini E; Costa A; Formelli F; Mariani L; Decensi A; Camerini T; Del Turco MR; Di Mauro MG; Muraca MG; Del Vecchio M; Pinto C; D'Aiuto G; Boni C; Campa T; Magni A; Miceli R; Perloff M; Malone WF; Sporn MB
J Natl Cancer Inst; 1999 Nov; 91(21):1847-56. PubMed ID: 10547391
[TBL] [Abstract][Full Text] [Related]
6. Fenretinide and risk reduction of second breast cancer.
Decensi A; Zanardi S; Argusti A; Bonanni B; Costa A; Veronesi U
Nat Clin Pract Oncol; 2007 Feb; 4(2):64-5. PubMed ID: 17259924
[No Abstract] [Full Text] [Related]
7. Effect of fenretinide on ovarian carcinoma occurrence.
De Palo G; Mariani L; Camerini T; Marubini E; Formelli F; Pasini B; Decensi A; Veronesi U
Gynecol Oncol; 2002 Jul; 86(1):24-7. PubMed ID: 12079295
[TBL] [Abstract][Full Text] [Related]
8. Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide.
Costa A; De Palo G; Decensi A; Formelli F; Chiesa F; Nava M; Camerini T; Marubini E; Veronesi U
Ann N Y Acad Sci; 1995 Sep; 768():148-62. PubMed ID: 8526344
[No Abstract] [Full Text] [Related]
9. Fenretinide and cancer prevention.
Torrisi R; Decensi A
Curr Oncol Rep; 2000 May; 2(3):263-70. PubMed ID: 11122852
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of breast cancer with fenretinide.
Veronesi U; De Palo G; Costa A; Formelli F; Decensi A
IARC Sci Publ; 1996; (136):87-94. PubMed ID: 8791119
[No Abstract] [Full Text] [Related]
11. Fenretinide in the prevention of breast cancer in premenopausal women: fluke or fact?
Pritchard KI
Ann Oncol; 2006 Jul; 17(7):1035-6. PubMed ID: 16766581
[No Abstract] [Full Text] [Related]
12. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.
Costa A; Formelli F; Chiesa F; Decensi A; De Palo G; Veronesi U
Cancer Res; 1994 Apr; 54(7 Suppl):2032s-2037s. PubMed ID: 8137334
[TBL] [Abstract][Full Text] [Related]
13. [-Results of ongoing breast cancer prevention studies-].
Jungi WF
Arch Gynecol Obstet; 1995; 256 Suppl():S116-21. PubMed ID: 8619644
[No Abstract] [Full Text] [Related]
14. Chemoprevention of second primary tumours in head and neck cancer in Europe: EUROSCAN.
de Vries N; Pastorino U; van Zandwijk N
Eur J Cancer B Oral Oncol; 1994 Nov; 30B(6):367-8. PubMed ID: 7719218
[No Abstract] [Full Text] [Related]
15. Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?
Cazzaniga M; Varricchio C; Montefrancesco C; Feroce I; Guerrieri-Gonzaga A
J Biomed Biotechnol; 2012; 2012():172897. PubMed ID: 22500077
[TBL] [Abstract][Full Text] [Related]
16. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
[TBL] [Abstract][Full Text] [Related]
17. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
Decensi A; Veronesi U; Miceli R; Johansson H; Mariani L; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Costa A; Perloff M; Malone WF; Formelli F
Clin Cancer Res; 2003 Oct; 9(13):4722-9. PubMed ID: 14581342
[TBL] [Abstract][Full Text] [Related]
18. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer.
Veronesi U; Mariani L; Decensi A; Formelli F; Camerini T; Miceli R; Di Mauro MG; Costa A; Marubini E; Sporn MB; De Palo G
Ann Oncol; 2006 Jul; 17(7):1065-71. PubMed ID: 16675486
[TBL] [Abstract][Full Text] [Related]
19. Adiponectin: a risk biomarker and attractive target for chemoprevention.
Fabian CJ
J Clin Oncol; 2012 Jan; 30(2):124-6. PubMed ID: 22162567
[No Abstract] [Full Text] [Related]
20. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
Formelli F
J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
